Compare
Milestone Pharmaceuticals Inc. vs Korro Bio, Inc. vs Rezolute, Inc. vs Avalo Therapeutics, Inc.
| Latest fiscal year | Milestone Pharmaceuticals Inc. MIST | Korro Bio, Inc. KRRO | Rezolute, Inc. RZLT | Avalo Therapeutics, Inc. AVTX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-06-30 | 2025-12-31 |
| Revenue | n/a | $6.39M | n/a | $59.0K |
| Revenue growth (YoY) | n/a | +181.5% | n/a | -86.6% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/m | n/a | n/m |
| Net margin | n/a | n/m | n/a | n/m |
| Net income | -$63.06M | -$117.26M | -$77.59M | -$78.26M |
| EPS (Diluted) | -$0.75 | -$12.48 | -$0.75 | -$5.84 |
| Operating cash flow | -$49.04M | -$78.56M | -$64.64M | -$51.46M |
| Free cash flow | -$49.34M | -$79.08M | n/a | n/a |
| Cash & equivalents | $73.05M | $21.82M | $10.62M | $15.86M |
| Total assets | $113.56M | $113.51M | $112.85M | $116.46M |
| Total liabilities | $71.79M | $62.07M | $12.16M | $33.41M |
| Shareholders' equity | $41.77M | $51.44M | $100.69M | $83.05M |
| Return on year-end equity | -151.0% | -228.0% | -77.1% | -94.2% |
| Shares outstanding | 106.24M | 9.42M | 96.41M | 18.51M |
Revenue, most recent five fiscal years
| Fiscal year | Milestone Pharmaceuticals Inc. | Korro Bio, Inc. | Rezolute, Inc. | Avalo Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | $6.39M Ended 2025-12-31 | n/a | $59.0K Ended 2025-12-31 |
| 1 year earlier | n/a | $2.27M Ended 2024-12-31 | n/a | $441.0K Ended 2024-12-31 |
| 2 years earlier | n/a | $0 Ended 2023-12-31 | n/a | $1.92M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | n/a | $18.05M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | n/a | $5.40M Ended 2021-12-31 |